These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 33864021)

  • 1. Janus-faced EPHB4-associated disorders: novel pathogenic variants and unreported intrafamilial overlapping phenotypes.
    Martin-Almedina S; Ogmen K; Sackey E; Grigoriadis D; Karapouliou C; Nadarajah N; Ebbing C; Lord J; Mellis R; Kortuem F; Dinulos MB; Polun C; Bale S; Atton G; Robinson A; Reigstad H; Houge G; von der Wense A; Becker WH; Jeffery S; Mortimer PS; Gordon K; Josephs KS; Robart S; Kilby MD; Vallee S; Gorski JL; Hempel M; Berland S; Mansour S; Ostergaard P
    Genet Med; 2021 Jul; 23(7):1315-1324. PubMed ID: 33864021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SAM domain variants of EPHB4 associated with aberrant signaling are linked to lymphatic-related fetal hydrops and facial dysmorphology.
    Vanden Broek K; Ryu JR; Perrier R; Tyndall AV; Childs SJ; Au PYB
    Clin Genet; 2024 Apr; 105(4):386-396. PubMed ID: 38151336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Germline Loss-of-Function Mutations in EPHB4 Cause a Second Form of Capillary Malformation-Arteriovenous Malformation (CM-AVM2) Deregulating RAS-MAPK Signaling.
    Amyere M; Revencu N; Helaers R; Pairet E; Baselga E; Cordisco M; Chung W; Dubois J; Lacour JP; Martorell L; Mazereeuw-Hautier J; Pyeritz RE; Amor DJ; Bisdorff A; Blei F; Bombei H; Dompmartin A; Brooks D; Dupont J; González-Enseñat MA; Frieden I; Gérard M; Kvarnung M; Hanson-Kahn AK; Hudgins L; Léauté-Labrèze C; McCuaig C; Metry D; Parent P; Paul C; Petit F; Phan A; Quere I; Salhi A; Turner A; Vabres P; Vicente A; Wargon O; Watanabe S; Weibel L; Wilson A; Willing M; Mulliken JB; Boon LM; Vikkula M
    Circulation; 2017 Sep; 136(11):1037-1048. PubMed ID: 28687708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EPHB4 kinase-inactivating mutations cause autosomal dominant lymphatic-related hydrops fetalis.
    Martin-Almedina S; Martinez-Corral I; Holdhus R; Vicente A; Fotiou E; Lin S; Petersen K; Simpson MA; Hoischen A; Gilissen C; Jeffery H; Atton G; Karapouliou C; Brice G; Gordon K; Wiseman JW; Wedin M; Rockson SG; Jeffery S; Mortimer PS; Snyder MP; Berland S; Mansour S; Makinen T; Ostergaard P
    J Clin Invest; 2016 Aug; 126(8):3080-8. PubMed ID: 27400125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second Report of the p.Leu874Pro Missense Variant in EPHB4 in a Family With Capillary Malformation-Arteriovenous Malformation Syndrome (CM-AVM) Syndrome.
    Goeser LE; Lalor L; Chiu YE; Muriello M
    Am J Med Genet A; 2024 Oct; ():e63898. PubMed ID: 39431828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenic variant in EPHB4 results in central conducting lymphatic anomaly.
    Li D; Wenger TL; Seiler C; March ME; Gutierrez-Uzquiza A; Kao C; Bhoj E; Tian L; Rosenbach M; Liu Y; Robinson N; Behr M; Chiavacci R; Hou C; Wang T; Bakay M; Pellegrino da Silva R; Perkins JA; Sleiman P; Levine MA; Hicks PJ; Itkin M; Dori Y; Hakonarson H
    Hum Mol Genet; 2018 Sep; 27(18):3233-3245. PubMed ID: 29905864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correction: Janus-faced EPHB4-associated disorders: novel pathogenic variants and unreported intrafamilial overlapping phenotypes.
    Martin-Almedina S; Ogmen K; Sackey E; Grigoriadis D; Karapouliou C; Nadarajah N; Ebbing C; Lord J; Mellis R; Kortuem F; Dinulos MB; Polun C; Bale S; Atton G; Robinson A; Reigstad H; Houge G; von der Wense A; Becker WH; Jeffery S; Mortimer PS; Gordon K; Josephs KS; Robart S; Kilby MD; Vallee S; Gorski JL; Hempel M; Berland S; Mansour S; Ostergaard P
    Genet Med; 2021 Jul; 23(7):1376-1377. PubMed ID: 34040196
    [No Abstract]   [Full Text] [Related]  

  • 8. Assessing the association of common genetic variants in EPHB4 and RASA1 with phenotype severity in familial cerebral cavernous malformation.
    Choksi F; Weinsheimer S; Nelson J; Pawlikowska L; Fox CK; Zafar A; Mabray MC; Zabramski J; Akers A; Hart BL; Morrison L; McCulloch CE; Kim H
    Mol Genet Genomic Med; 2021 Oct; 9(10):e1794. PubMed ID: 34491620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EPHB4 Mutation Suppresses PROX1 Expression and Disrupts Lymphatic Development in Neonatal Hydrops.
    Akangire G; Menden H; Xia S; Thiffault I; Ahmed A; Sampath V
    Pediatrics; 2022 Mar; 149(3):. PubMed ID: 35178555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EPHB4 mutation causes adult and adolescent-onset primary lymphedema.
    Greene AK; Brouillard P; Sudduth CL; Smits PJ; Konczyk DJ; Vikkula M
    Am J Med Genet A; 2021 Dec; 185(12):3810-3813. PubMed ID: 34231312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unilateral and segmental distribution of facial erythema: is it a real port-wine stain?
    Cen Q; Sun Y; Zeng X; Liu Y; Liu F; Chen H; Lin X; Cai R
    Hereditas; 2020 Jul; 157(1):27. PubMed ID: 32635943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ephrin B2 and EphB4 selectively mark arterial and venous vessels in cerebral arteriovenous malformation.
    Bai J; Wang YJ; Liu L; Zhao YL
    J Int Med Res; 2014 Apr; 42(2):405-15. PubMed ID: 24517927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dysregulation of the EphrinB2-EphB4 ratio in pediatric cerebral arteriovenous malformations is associated with endothelial cell dysfunction in vitro and functions as a novel noninvasive biomarker in patients.
    Fehnel KP; Penn DL; Duggins-Warf M; Gruber M; Pineda S; Sesen J; Moses-Gardner A; Shah N; Driscoll J; Zurakowski D; Orbach DB; Smith ER
    Exp Mol Med; 2020 Apr; 52(4):658-671. PubMed ID: 32286515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinome multigenic panel identified novel druggable EPHB4-V871I somatic variant in high-risk neuroblastoma.
    Andolfo I; Lasorsa VA; Manna F; Rosato BE; Formicola D; Iolascon A; Capasso M
    J Cell Mol Med; 2020 Jun; 24(11):6459-6471. PubMed ID: 32336043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EPHB4 Mutation Implicated in Capillary Malformation-Arteriovenous Malformation Syndrome: A Case Report.
    Yu J; Streicher JL; Medne L; Krantz ID; Yan AC
    Pediatr Dermatol; 2017 Sep; 34(5):e227-e230. PubMed ID: 28730721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for a dual function of EphB4 as tumor promoter and suppressor regulated by the absence or presence of the ephrin-B2 ligand.
    Rutkowski R; Mertens-Walker I; Lisle JE; Herington AC; Stephenson SA
    Int J Cancer; 2012 Sep; 131(5):E614-24. PubMed ID: 22161689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case of capillary malformation-arteriovenous malformation and Ebstein's anomaly in a child with EphB4 mutation.
    Sherwani Y; Jenkins S; Adelanwa A; Burch DM; Chaudhuri NR; Zinn Z
    Pediatr Dermatol; 2021 Sep; 38(5):1305-1307. PubMed ID: 34339071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receptor tyrosine kinase EphB4 is a survival factor in breast cancer.
    Kumar SR; Singh J; Xia G; Krasnoperov V; Hassanieh L; Ley EJ; Scehnet J; Kumar NG; Hawes D; Press MF; Weaver FA; Gill PS
    Am J Pathol; 2006 Jul; 169(1):279-93. PubMed ID: 16816380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EphrinB2-EphB4 signalling provides Rho-mediated homeostatic control of lymphatic endothelial cell junction integrity.
    Frye M; Stritt S; Ortsäter H; Hernandez Vasquez M; Kaakinen M; Vicente A; Wiseman J; Eklund L; Martínez-Torrecuadrada JL; Vestweber D; Mäkinen T
    Elife; 2020 Sep; 9():. PubMed ID: 32897857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down-regulation of EphB4 phosphorylation is necessary for esophageal squamous cell carcinoma tumorigenecity.
    Hu F; Tao Z; Shen Z; Wang X; Hua F
    Tumour Biol; 2014 Jul; 35(7):7225-32. PubMed ID: 24771266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.